ERBB2 and triple-negative breast carcinoma: Concerning HR– tumors (namely triple-negative breast cancer, TNBC), some studies have shown, like ours, a non-significant trend towards more pCR in HER2-0 tumors compared to HER2-low [15, 20, 23, 24], in contradiction with other studies [25].